Off-label prescribing of semaglutide for weight loss is evidence-based, legal, and increasingly common in clinical practice
Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni LV, et al
Recent concerns have emerged about whether Mounjaro causes suicidal thoughts, prompting regulatory reviews by the MHRA and EMA
Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
Presented for research literature review only Kentroti S et al
Timothy Garvey, MD, FACE Professor of Medicine University of Alabama at Birmingham Disclosures: Garvey reports conducting clinical trials funded by his institution for Eli Lilly, Epitomee, Novo Nordisk and Pfizer and serving as a volunteer on advisory board without receipt of financial compensation for Eli Lilly, Novo Nordisk, JAZZ Pharmaceuticals and Boehringer Ingelheim